Laniquidar

Laniquidar (INN) is a P-glycoprotein inhibitor that underwent clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).[1]

Laniquidar
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • methyl 11-(1-{2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl}piperidin-4-ylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC37H36N4O3
Molar mass584.720 g·mol−1
3D model (JSmol)
SMILES
  • COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6
InChI
  • InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
  • Key:TULGGJGJQXESOO-UHFFFAOYSA-N
  (verify)

References
  1. Ross DD (December 2004). "Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome". Best Practice & Research. Clinical Haematology. 17 (4): 641–51. doi:10.1016/j.beha.2004.08.014. PMID 15494300.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.